You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Pharmacologic Suppression of Reperfusion Injury Following Endovascular Thrombectomy In Stroke.

    SBC: BIOMIMETIX JV LLC            Topic: 102

    Ischemic stroke is a leading cause of death and disability in the United StatesThis often is attributable to thrombus formation at an atherosclerotic plaque or thromboembolismPatients who present withinhours of symptom onset are eligible for thrombolysis with tissue plasminogen activatortPAThis serves andltof victimsRecentlymajor advance has been made with proven efficacy from endovascular mechani ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Targeting lipid rafts for treatment of migraine

    SBC: RAFT PHARMACEUTICALS LLC            Topic: NINDS

    PROJECT SUMMARY Migraine is a highly prevalent condition with an extraordinarily negative impact on quality of life and represents a heavy socioeconomic burden to the societyprimarily because of decreased working efficiency and workdays lostManagement of migraine has become increasingly pharmacological during recent yearsWhile several therapeutic options existmost of the prophylactic drugs current ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Novel monoclonal antibody for single dose treatment of acute CNS injury

    SBC: OncoSynergy, Inc.            Topic: NINDS

    PROJECT SUMMARY Traumatic brain injuryTBIrepresents a significant societal and economic impactTo datethere are no FDAapproved pharmacotherapies to prevent or reverse TBIThe standard of care in an emergency setting focuses first on stabilizing the patient and secondly on management of cerebral hemodynamicsThe patient may undergo surgery to remove hematomasrepair skull fracturesand relieve intracran ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Pre-clinical evaluation of DT-001, a small molecule antagonist of MD2-TLR4 for utility in the treatment of pain.

    SBC: Douleur Therapeutics Inc            Topic: NINDS

    Project Summary AbstractUpwards ofmillion individuals are afflicted by chronic pain in the US alonewithmillion of these individuals suffering from neuropathic painOn a global scalechronic pain affectsbillion individualswithwho endure lower back painFrom a clinical perspectivethe International Association for the Study of Pain approximates thatinpatients present with painand on an annual basisinpat ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Extending WAAVES+: An animal and environment-agnostic, automated USV scoring platform for high-throughput social, behavioral, and neuropharmacological studies

    SBC: Cornerstone Research Group, Incorporated            Topic: 101

    Project SummaryUltrasonic vocalizationsUSVsare known to reflect emotional processingbrain neurochemistry and brain functionkey observations in animal model studiesCollecting and processing USV data is time intensivemanualand costlyMost importantlyit limits researchersability to employ fully effectiveand nuanced experimental designsand is a barrier to entry for other researchersAutomated tabulation ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. NOVO-118 as a therapeutic to promote remyelination in in vivo models of MS

    SBC: Novoron Bioscience Inc.            Topic: NINDS

    Project Summary Multiple sclerosisMSis a neurodegenerative disease in which myelin of the central nervous systemCNSis destroyed by a self reactive immune responseThis demyelination is accompanied by the death of the myelinating cells themselvesthe oligodendrocytesRepeated bouts of demyelination leave the denuded CNS neurons vulnerable to degradation and is the major cause of neuronal dysfunction a ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Targeting lipid rafts for treatment of asthma

    SBC: RAFT PHARMACEUTICALS LLC            Topic: NIAID

    PROJECT SUMMARY Asthmacharacterized by airways obstruction with symptoms of wheezingshortness of breathchest tightness and consequently coughremains a significant health problemWhile advances in bronchodilatorcorticosteroid and Thtargeting therapy allow for well controlled asthma in a large population of patientssubjects with severecorticosteroid resistant asthma require frequent hospitalizations ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. DR?1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder

    SBC: Virogenomics BioDevelopment Inc            Topic: R41

    Methamphetamine use disorder is associated with damage to regions of the brain that control cognitive and psychiatric functionOne third to one half of adults with methamphetamine use disorder experience cognitive impairments and other psychiatric symptoms that significantly impact treatment outcomesincreased relapse and lower treatment retention ratesMounting evidence demonstrates how immune facto ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    ABSTRACT TypeDiabetes MellitusT DMaffectsmillion patients in US withnew patients annuallyLifespan is shortenedyearsdue to kidney and heart diseaseTight glucose control reduces microvascular complications and adverse cardiovascular eventsInsulin therapy is essential for such patientsbut has shortcomingsaonlyinpatients achieve targeted glucose controlHbA c andltbaggressive insulin therapy increases ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Stem Cells for Treating Acute Stroke

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: 999

    ABSTRACT SUMMARY In previous studies we identified novel non hematopoietic umbilical cord blood stem cellsnhUCBSCsthat could be expanded to high passages and exhibit restorative properties following ischemic brain injury repairWe found that the high passaged cells were equivalentif not even betterthan the low passaged nh UCBSCsThis finding suggests that these cells can serve as a source of highly ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government